Austrália - inglês - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - furosemide, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - indications as at 01 jan 1991 : oedema : in adults, infants and children frusemide is indicated for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver, renal disease including nephrotic syndrome and other oedematous states amenable to diuretic therapy. hypertension : may also be used alone in the control of mild to moderate hypertension and in combination with other antihypertensive agents in the treatment of more severe cases. studies have shown that frusemide is either less effective than or equally effective as thiazide diuretics in uncomplicated hypertension. however, in patients with severe renal function impairment, a diuretic and antihypertensive response to frusemide may be achieved while thiazides have no effect.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - furosemide, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - indications as at 01 jan 1991 : oedema : in adults, infants and children frusemide is indicated for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver, renal disease including nephrotic syndrome and other oedematous states amenable to diuretic therapy. hypertension : may also be used alone in the control of mild to moderate hypertension and in combination with other antihypertensive agents in the treatment of more severe cases. studies have shown that frusemide is either less effective than or equally effective as thiazide diuretics in uncomplicated hypertension. however, in patients with severe renal function impairment, a diuretic and antihypertensive response to frusemide may be achieved while thiazides have no effect.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide (frusemide) -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: povidone; crospovidone; sodium hydroxide; lactose monohydrate; meglumine; colloidal anhydrous silica; magnesium stearate - telmisartan is indicated for:,treatment of hypertension ,prevention of cardiovascular morbidity and mortality in patients 55 years or older with,coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic,attack or high risk diabetes with evidence of end organ damage.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: meglumine; lactose monohydrate; povidone; magnesium stearate; crospovidone; colloidal anhydrous silica; sodium hydroxide - telmisartan is indicated for:,treatment of hypertension ,prevention of cardiovascular morbidity and mortality in patients 55 years or older with,coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic,attack or high risk diabetes with evidence of end organ damage.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: magnesium stearate; crospovidone; lactose monohydrate; meglumine; colloidal anhydrous silica; sodium hydroxide; povidone - telmisartan is indicated for:,treatment of hypertension ,prevention of cardiovascular morbidity and mortality in patients 55 years or older with,coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic,attack or high risk diabetes with evidence of end organ damage.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; crospovidone; povidone; sodium hydroxide; meglumine; colloidal anhydrous silica; magnesium stearate - telmisartan is indicated for:,treatment of hypertension ,prevention of cardiovascular morbidity and mortality in patients 55 years or older with,coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic,attack or high risk diabetes with evidence of end organ damage.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - furosemide, quantity: 20 mg - tablet - excipient ingredients: pregelatinised maize starch; lactose monohydrate; sodium starch glycollate type a; maize starch; magnesium stearate - oedema frusemide is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired.,parenteral therapy with frusemide should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous or intramuscular route. parenteral use should be replaced with oral frusemide as soon as practical.,hypertension oral frusemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with frusemide alone.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - furosemide, quantity: 40 mg - tablet - excipient ingredients: lactose monohydrate; pregelatinised maize starch; sodium starch glycollate type a; magnesium stearate; maize starch - oedema frusemide is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired.,parenteral therapy with frusemide should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous or intramuscular route. parenteral use should be replaced with oral frusemide as soon as practical.,hypertension oral frusemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with frusemide alone.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - azathioprine, quantity: 25 mg - tablet, film coated - excipient ingredients: purified talc; lactose monohydrate; magnesium stearate; maize starch; povidone; colloidal anhydrous silica; titanium dioxide; hypromellose; microcrystalline cellulose; peg-8 stearate - immunosuppressant antimetabolite: either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with higher dosage and prolonged usage of corticosteroids. azathioprine, in combination with cortocosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura.